German panel recommends booster for recipients of 4 vaccines
Germany’s independent vaccination advisory panel is recommending a booster shot with a messenger RNA vaccine for people who have had a full course of four Chinese, Indian and Russian COVID-19 vaccines that aren’t currently approved for use in the European Union
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Germany's independent vaccination advisory panel is recommending a booster shot with a messenger RNA vaccine for people who have had a full course of four Chinese, Indian and Russian COVID-19 vaccines that aren't currently approved for use in the European Union.
In a draft recommendation Thursday, the panel, known by its German acronym STIKO, said the advice applies to people given a full course and also a booster of the Chinese Sinovac and Sinopharm vaccines, the Indian-made Covaxin and Russia's Sputnik V.
It said that the new booster shot should be administered at least three months after the previous vaccination.
The German panel said that people who have received only a single shot of the four vaccines should start a new vaccination series.
And it added that recipients of other vaccines not cleared by the EU should in general start a new series with a vaccine European authorities have approved.
Scientists believe that mixing and matching vaccines prompts a better immune response.
The BioNTech-Pfizer and Moderna mRNA vaccines have been the mainstay of Germany's vaccination program. Three other vaccines using different technologies have been cleared for use in the 27-nation EU — the AstraZeneca, Johnson & Johnson and Novavax products.
The mRNA vaccines have shown to be better than others at protecting against newer variants like omicron.
___
Follow AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic